FDA advisory panel recommends approval of TB Alliance’s tuberculosis treatment
Independent experts of an FDA advisory panel voted in favor of the not-for-profit TB Alliance’s treatment for drug resistant tuberculosis, as a part of a three-drug combination regimen.
The panel on Tuesday voted 14-4 when asked to assess the treatment, pretomanid, in combination with Johnson & Johnson’s bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).
Although the U.S. health regulator is not bound to follow the advice of its advisory panels, it usually does so.
Join the AMR Insights Ambassador Network today!
Connect to over 650 AMR professionals and students in 65 countries!